Replet Plus: An Anti-platelet Combination (Clopidogrel + Aspirin)

Replet Plus is a combination medication containing Clopidogrel and Aspirin, both of which are anti-platelet drugs. It is indicated to reduce the rate of Myocardial Infarction (MI) and Stroke in patients with Acute Coronary Syndrome (ACS) and in those with a history of recent MI, recent Stroke, or established Peripheral Arterial Disease. It belongs to the therapeutic class of Anti-platelet drugs.

How Replet Plus Works (Pharmacology)

Replet Plus combines two anti-platelet agents with distinct mechanisms of action:

• Clopidogrel:
  • It is a prodrug that, once metabolized, irreversibly binds to the P2Y12 class of ADP receptors on platelets.
  • This binding inhibits platelet activation and aggregation, preventing the formation of blood clots.
  • Dose-dependent inhibition of platelet aggregation can be seen within 2 hours. Steady-state inhibition is reached between Day 3 and Day 7 with repeated 75 mg doses.
• Aspirin:
  • It irreversibly inhibits platelet cyclooxygenase (COX).
  • This inhibition prevents the generation of thromboxane A2 (TxA2), a powerful inducer of platelet aggregation and vasoconstriction.

The combination provides a dual anti-platelet effect, more comprehensively inhibiting platelet aggregation.

Key Indications & Benefits

Replet Plus is indicated for:

• Acute Coronary Syndrome (ACS): To reduce the rate of Myocardial Infarction (MI) and Stroke in patients with:
  • Non-ST-segment elevation ACS (Unstable Angina/non-ST-elevation Myocardial Infarction - UA/NSTEMI).
  • Acute ST-segment elevation ACS (ST-elevation Myocardial Infarction - STEMI).
• Recent MI, recent Stroke, or established Peripheral Arterial Disease: To reduce the rate of MI and Stroke in patients with these conditions.

Dosage & Administration

The recommended dose of Clopidogrel is 75 mg once daily. For acute coronary syndrome, a loading dose is used. Aspirin (75 mg-325 mg) should be continued in combination. Always consult a registered physician for specific dosage instructions.

• General Dosage (Recent MI, Stroke, PAD):
  • Clopidogrel: 75 mg once daily with or without food.
  • No dosage adjustment is necessary for elderly patients or patients with renal impairment.
• Acute Coronary Syndrome (UA/NSTEMI or STEMI):
  • Clopidogrel: Initiate with a single 300 mg loading dose, then continue at 75 mg once daily.
  • Aspirin: 75 mg-325 mg once daily should be initiated and continued in combination.

Important Considerations & Warnings

It is crucial to discuss your full medical history with your doctor before taking Replet Plus.

Contraindications:

• Hypersensitivity to Clopidogrel, Aspirin, or any component of the product.
• Active pathological bleeding, such as peptic ulcer or intracranial hemorrhage.
• Third trimester of pregnancy.

Side Effects:

• Replet Plus is generally well tolerated. However, as an anti-platelet drug, the primary risk is bleeding.

Pregnancy & Lactation:

• Pregnancy:
  • First and second trimesters: Use only if clearly needed, as there are no adequate and well-controlled studies in pregnant women.
  • Third trimester:Contraindicated.
• Lactation: It is unknown whether Clopidogrel is excreted in human breast milk, but Aspirin is known to be excreted. This drug should be discontinued during breastfeeding.

Precautions & Warnings:

• Prolonged Bleeding Time: Replet Plus may prolong bleeding time. Use with caution in patients at increased risk of bleeding from trauma, surgery, or other pathological conditions.
• Thrombotic Thrombocytopenic Purpura (TTP): TTP, a rare but serious condition, has been reported rarely following use.
• Reye's Syndrome: Reye's syndrome may develop in individuals (especially children under 12) who have chickenpox, influenza, or flu-like symptoms, particularly with Aspirin use.
• Hypersensitivity: Hypersensitivity reactions, including rash, angioedema, or hematologic reactions, have been reported in patients receiving Replet Plus or with a history of hypersensitivity to other thienopyridines (like ticlopidine).

Drug Interactions:

• Aspirin: Does not modify Clopidogrel's inhibition of ADP-induced platelet aggregation but Clopidogrel potentiates Aspirin's effect on collagen-induced platelet aggregation.
• Heparin: No significant interaction; does not necessitate modification of heparin dose or alter its effect.
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Concomitant administration is associated with increased occult gastrointestinal blood loss. NSAIDs and Clopidogrel should be co-administered with caution.
• Warfarin: The safety of co-administration has not been established. Concomitant administration should be undertaken with caution due to increased bleeding risk.

Use in Special Populations

• Children: Should not be given to children, particularly those under 12 years, unless the expected benefits outweigh the possible risks. Aspirin may be a contributory factor in Reye's syndrome in some children.
• Elderly Patients / Renal Patients: No dosage adjustment is necessary.

Overdose Effects

• Clopidogrel overdose: May lead to bleeding complications. Platelet transfusion may restore clotting ability.
• Moderate Aspirin intoxication: Dizziness, headache, tinnitus, confusion, and gastrointestinal symptoms may occur. Treatment includes inducing vomiting followed by gastric lavage if needed.
• Severe Aspirin intoxication: Respiratory alkalosis, respiratory acidosis, metabolic acidosis, hyperthermia, perspiration, and dehydration can occur. Treatment involves hemodialysis and other symptomatic treatments.

Storage Conditions

Keep in a cool and dry place (below 30ºC), protected from light and moisture. Keep out of the reach of children.